Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 5Phase 2 5Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 2

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Carcinoma, Non-Small-Cell Lung 188Neoplasm Metastasis 152Neoplasms 141Leukemia, Myeloid, Acute 139Colorectal Neoplasms 132Breast Neoplasms 122Melanoma 96Ovarian Neoplasms 94Prostatic Neoplasms 89Recurrence 88Multiple Myeloma 84Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66Triple Negative Breast Neoplasms 58Glioma 58Stomach Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Endometrial Neoplasms 51Carcinoma, Renal Cell 49Brain Neoplasms 49Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 46Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 41Sarcoma 40

Interventions

venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Dexamethasone 1Calcium Dobesilate 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × 90 days × Clear all
NCT05839626 2026-05-27

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Sanofi

Phase 1 Terminated
32 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07250269 2026-04-28

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Gracell Biotechnologies (Shanghai) Co., Ltd.

Phase 1 Recruiting
9 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡